Aim: To assess CML patient's characteristic including demographic, clinical and hematological characteristic of patients with CML including quantitative BCR-ABL and BCR-ABL gene sequencing. Methods: This study was an open-label, single arm, non-randomized, cross sectional study in patients with CML being treated with imatinib mesylate (IM) from 12 centers. Result: A total of 100 patients were evaluated between January 1, 2009 and December 31, 2011. The median age was 34-35 years old (mean of age is 36 years old), and more patients in the productive age was found.-(?) were 80 of the 100 patients who had been examined for the BCR-ABL gene mutation with the sequencing method before consuming IM. Mutation in the P-loop was seen in 2,27% (1 out of 44 patients), this finding was beyond our expectation since 47,69% (31 out of 65 patients) of our patients did not achieved CHR at three months. On the other hand, 15,9% (7 out of 44 patients) of our patients had mutation outside the P-loop. Conclusions: The characteristics of CML patients in Indonesia were not different from CML patients in Asia in general. Our finding concerning the high frequency mutation in the BCR-ABL gene outside the P-loop needs further study.

dr. Cipto Mangunkusumo (RSCM) Jakarta yang telah menjalani pemeriksaan sitogenetika dan/atau RT-PCR BCR-ABL, akan menunjukkan LGK Ph (+)/BCR-ABL (+) dan LGK bentuk kelainan Ph/ BCR-ABL lainnya. Penelitian ini dilakukan untuk mengetahui hubungan gambaran klinis dan laboratorium hematologis antara LGK Ph (+)/BCR-ABL (+) dengan LGK bentuk kelainan Ph/BCR-ABL lainnya. Metode. Studi potong lintang dilakukan pada pasien LGK yang dirawat di RSCM Jakarta. Sampel penelitian diambil dengan metode consecutive dan dianalisis menggunakan uji Chi-square dan regresi logistik dengan menggunakan SPSS 20 for windows. Hubungan antarvariabel dinyatakan bermakna apabila nilai p<0,05. Hasil. Dari total 80 subjek LGK fase kronik, didapatkan rerata usia yaitu 39,4 (simpang baku 13,1) tahun. Didapatkan perbandingan gambaran klinis dan laboratorium hematologis antara LGK Ph (+)/BCR-ABL (+) dan LGK bentuk kelainan Ph/BCR-ABL lainnya, yaitu: keluhan yang simtomatik 80,6%: 100%; splenomegali 82% : 92,3%; median Hb 10,3 g/dL : 10,3 g/dL; median leukosit 124.620 : 127.050, median trombosit 455.000 : 487.000. Namun demikian, hasil analisis bivariat dan multivariat menunjukkan tidak ada variabel gambaran klinis dan laboratorium hematologis yang berhubungan bermakna. Simpulan. Tidak ada variabel gambaran klinis dan laboratorium hematologis yang berhubungan bermakna antara LGK Ph(+)/BCR-ABL (+) dengan LGK bentuk kelainan Ph/BCR-ABL lainnya.

Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome and BCR-ABL fusion oncogene. CML is one of the illnesses that may be treated using Tyrosine Kinase Inhibitors (TKIs), a type of targeted therapy. Since TKIs are the standard of therapy, long-term survival of CML has improved compared to chemotherapy and interferon-alpha. For the first-line treatment for CML, there are four commercially available TKIs that serve as an integral part of the disease management. However, there are many challenges in diagnosing, treating, and monitoring patients with chronic phase CML in Indonesia. This study highlights the epidemiology data of chronic phase CML patients, particularly at Dr. Cipto Mangunkusumo General Hospital, an Indonesian national referral hospital, and how to diagnose, select first-line TKIs, and monitor the response of treatment after TKIs administration.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.